本妥昔单抗治疗复发的原发性纵隔大B细胞淋巴瘤：一项2期临床试验的结果 - Suppr

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

作者信息

Zinzani Pier Luigi, Pellegrini Cinzia, Chiappella Annalisa, Di Rocco Alice, Salvi Flavia, Cabras Maria Giuseppina, Argnani Lisa, Stefoni Vittorio

机构信息

Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

Hematology Unit, Città della Salute e della Scienza Hospital and University, Turin, Italy.

出版信息

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6.

DOI:10.1182/blood-2017-01-764258

PMID:28264798

Abstract

摘要

相似文献

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6.

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.

Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.

Haematologica. 2024 Sep 1;109(9):3019-3023. doi: 10.3324/haematol.2023.284689.

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.

J Cancer Res Ther. 2020 Jan-Mar;16(1):183-185. doi: 10.4103/jcrt.JCRT_696_16.

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.

A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.

Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.

Blood. 2023 Jun 1;141(22):2780-2783. doi: 10.1182/blood.2022017951.

Primary mediastinal large B-cell lymphoma.

South Med J. 2002 Sep;95(9):1005-7.

引用本文的文献

Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.

J Clin Med. 2025 Feb 11;14(4):1191. doi: 10.3390/jcm14041191.

Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.

Onco Targets Ther. 2025 Jan 6;18:1-14. doi: 10.2147/OTT.S487088. eCollection 2025.

Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study.

Int J Clin Oncol. 2024 Dec;29(12):1977-1983. doi: 10.1007/s10147-024-02627-8. Epub 2024 Sep 18.

Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.

Haematologica. 2024 Nov 1;109(11):3790-3794. doi: 10.3324/haematol.2024.285403.

Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review.

J Int Med Res. 2024 Jun;52(6):3000605241258597. doi: 10.1177/03000605241258597.

Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.

Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.

Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.

Haematologica. 2024 Sep 1;109(9):3019-3023. doi: 10.3324/haematol.2023.284689.

[Progress in treatment of primary mediastinal large B-cell lymphoma].

Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):98-102. doi: 10.3760/cma.j.cn121090-20230731-00041.

Mature B-cell lymphomas in adolescents and young adults.

EJHaem. 2023 Sep 8;4(4):912-920. doi: 10.1002/jha2.783. eCollection 2023 Nov.

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.

Cancers (Basel). 2023 Nov 14;15(22):5399. doi: 10.3390/cancers15225399.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

作者信息

Zinzani Pier Luigi, Pellegrini Cinzia, Chiappella Annalisa, Di Rocco Alice, Salvi Flavia, Cabras Maria Giuseppina, Argnani Lisa, Stefoni Vittorio

机构信息

Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

Hematology Unit, Città della Salute e della Scienza Hospital and University, Turin, Italy.

出版信息

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6.

DOI:10.1182/blood-2017-01-764258

PMID:28264798

Abstract

摘要

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献